Drug Trial Radar · NCT03579836
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
May 14, 2018
Primary completion
Nov 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- BeyondBio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.
Conditions
- Locally Advanced or Metastatic Pancreatic Cancer
Interventions
BEY1107Drug
Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
GemcitabineCombination product
Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD & Safety assessment (Phase I)Time frame: 0
- DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II)Time frame: 0
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yonsei University Health System Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.